Lymphoma - systemic anaplastic large cell lymphoma

The PBS subsidises brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the National Health Act 1953, section 100 for patients with CD30 positive sALCL.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing brentuximab vedotin.

Section 100 arrangements

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe brentuximab vedotin to treat CD30 positive sALCL in writing and either:

All written applications must include the completed:

Continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised brentuximab vedotin to treat CD30 positive sALCL can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 September 2021